- Joined
- Oct 28, 2008
- Messages
- 2,569
- Reaction score
- 40
USA Today (2/10, Rubin) reports, "The Food and Drug Administration [FDA] announced Monday that it was stepping up efforts to reduce unsafe use of 24 narcotics products -- methadone pills, fentanyl patches and extended-release pills containing morphine, oxymorphone and oxycodone, such as OxyContin."
The "products are classified as Schedule II narcotics and already are restricted according to rules jointly administered by the [FDA] and the Drug Enforcement Agency [DEA]," the New York Times (2/10, A13, Harris) adds. But, according to Dr. John K. Jenkins, director of the FDA's new drug center, "the current restrictions have failed to 'fully meet the goals we want to achieve.'"
The agency "has issued a number of warnings on prescription pain relievers in recent years and some companies already have plans to manage the drugs' risks," the AP (2/10, Perrone) notes. "Despite these efforts, the rates of misuse and abuse, and of accidental overdose of opioids, have risen over the past decade," Dr. Jenkins said. "According to [the] FDA, about 3.7 million patients were taking the drugs under scrutiny in 2007. A federal survey conducted that year found 5.2 million people in the U.S. reported using prescription pain drugs inappropriately."
The Wall Street Journal (2/10, Dooren) reports that "a major part of the new program will be efforts to educate doctors about appropriate prescribing of the products. 'This obviously is going to be the largest risk management program we've undertaken,'" Dr. Jenkins said. Although Dr. Jenkins and other FDA "officials wouldn't speculate about what the final risk-mitigation program would look like, it could have elements of a program designed to limit the use of the acne drug isotretinion (commonly known by the brand name Accutane) by women of child-bearing age because the product causes birth defects. That program requires doctors, pharmacists, and patients to register and meet certain requirements in order to get a new prescription each month." The FDA "sent letters to 16 manufacturers of 24 products. ... The letters told the drugmakers of agency plans to require a risk evaluation and mitigation strategy, or REMS, 'to ensure that the benefits of the drugs continue to outweigh the risks.'"
Dr. "Jenkins called the new program a multi-pronged and complex effort that will take several months to put in place, after an initial meeting with the drug manufacturers, scheduled for March 3," HealthDay (2/9, Mozes) added.
"Additional steps will include discussions with other federal agencies -- such as the [DEA] -- patient and consumer advocates, representatives of the pain and addiction treatment communities, and other healthcare professionals," MedPage Today (2/9, Gever) noted. A "public meeting would be held in late spring or early summer to allow for broader public input and participation," according to Dr. Jenkins.
------------------------------------------------------------
Any idea how/when this might take effect? I think it's a pretty good idea overall, but I think it'll lead to quite a few unhappy patients and doctors alike.
The "products are classified as Schedule II narcotics and already are restricted according to rules jointly administered by the [FDA] and the Drug Enforcement Agency [DEA]," the New York Times (2/10, A13, Harris) adds. But, according to Dr. John K. Jenkins, director of the FDA's new drug center, "the current restrictions have failed to 'fully meet the goals we want to achieve.'"
The agency "has issued a number of warnings on prescription pain relievers in recent years and some companies already have plans to manage the drugs' risks," the AP (2/10, Perrone) notes. "Despite these efforts, the rates of misuse and abuse, and of accidental overdose of opioids, have risen over the past decade," Dr. Jenkins said. "According to [the] FDA, about 3.7 million patients were taking the drugs under scrutiny in 2007. A federal survey conducted that year found 5.2 million people in the U.S. reported using prescription pain drugs inappropriately."
The Wall Street Journal (2/10, Dooren) reports that "a major part of the new program will be efforts to educate doctors about appropriate prescribing of the products. 'This obviously is going to be the largest risk management program we've undertaken,'" Dr. Jenkins said. Although Dr. Jenkins and other FDA "officials wouldn't speculate about what the final risk-mitigation program would look like, it could have elements of a program designed to limit the use of the acne drug isotretinion (commonly known by the brand name Accutane) by women of child-bearing age because the product causes birth defects. That program requires doctors, pharmacists, and patients to register and meet certain requirements in order to get a new prescription each month." The FDA "sent letters to 16 manufacturers of 24 products. ... The letters told the drugmakers of agency plans to require a risk evaluation and mitigation strategy, or REMS, 'to ensure that the benefits of the drugs continue to outweigh the risks.'"
Dr. "Jenkins called the new program a multi-pronged and complex effort that will take several months to put in place, after an initial meeting with the drug manufacturers, scheduled for March 3," HealthDay (2/9, Mozes) added.
"Additional steps will include discussions with other federal agencies -- such as the [DEA] -- patient and consumer advocates, representatives of the pain and addiction treatment communities, and other healthcare professionals," MedPage Today (2/9, Gever) noted. A "public meeting would be held in late spring or early summer to allow for broader public input and participation," according to Dr. Jenkins.
------------------------------------------------------------
Any idea how/when this might take effect? I think it's a pretty good idea overall, but I think it'll lead to quite a few unhappy patients and doctors alike.